Real-world experience of the 6 weekly schedule (q6w) of pembrolizumab in patients (pts) with metastatic non-small cell lung cancer (mNSCLC)

被引：0
|
作者：
Tariq, Noor-Ul-Ain [1 ]
Anderson, Christian [2 ]
Gartside, Eleanor [1 ]
Wong, Helen [1 ]
Dobson, Lisa [1 ]
Anthonypillai, Marry [1 ]
Griffiths, Richard [1 ]
Pope, Anthony [1 ]
机构：
[1] Clatterbridge Canc Ctr, Liverpool, Merseyside, England
[2] Univ Liverpool, Clatterbridge, England
来源：
LUNG CANCER | 2022年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
80
引用
收藏
页码：S38 / S38
页数：1
相关论文
共 50 条
  • [1] Real-world use of different pembrolizumab regimens (3 weekly versus 6 weekly) in non-small cell lung cancer (NSCLC) patients
    Osborne, Lucy
    Ortega-Franco, Ana
    Hodgson, Clare
    Moss, Pearce Mark
    Moss, Anna
    Lindsay, Colin
    Hughes, Sarah
    Taylor, Paul
    Califano, Raffaele
    Rafee, Shereen
    Gomes, Fabio
    Summers, Yvonne
    Blackhall, Fiona
    Cove-Smith, Laura
    Halkyard, Emma
    Fenemore, Jackie
    LUNG CANCER, 2022, 165 : S46 - S46
  • [2] Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom
    Lester, J.
    Escriu, C.
    Khan, S.
    Hudson, E.
    Mansy, T.
    Conn, A.
    Chan, S.
    Powell, C.
    Brock, J.
    Conibear, J.
    Nelless, L.
    Nayar, V.
    Zhuo, X.
    Durand, A.
    Amin, A.
    Martin, P.
    Zhang, X.
    Pawar, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S878 - S879
  • [3] Safety of pembrolizumab in patients with non-small cell lung cancer: a real-world study
    Thakrar, D. B.
    Essang, B.
    Echlin, A.
    Murdock, C.
    Lind, M. J.
    LUNG CANCER, 2019, 127 : S40 - S41
  • [4] Real-world treatment outcomes with brigatinib in patients with pretreated ALK plus metastatic non-small cell lung cancer (mNSCLC)
    Popat, S.
    Brustugun, T.
    Cadranel, J.
    Felip, E.
    Garassino, M. C.
    Griesinger, F.
    Helland, A.
    Hochmair, M. J.
    Perol, M.
    Bent-Ennakhil, N.
    Kruhl, C.
    Novello, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S866 - S866
  • [5] Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer (MNSCLC) with Brain Metastases Treated with Pembrolizumab
    Sun, L.
    Davis, C.
    Marmarelis, M.
    Singh, A.
    Berman, A.
    Feigenberg, S.
    Levin, W.
    Bauml, J.
    Cohen, R.
    Langer, C.
    Aggarwal, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1131 - S1131
  • [6] Experience of nivolumab and pembrolizumab in metastatic non-small cell lung cancer in routine clinical practice (mNSCLC.)
    Ksienski, Doran
    Brooks, Edward Geoffrey
    Fenton, Dave
    Fiorino, Leathia
    Geller, Georgia Samantha
    Poonja, Zia
    Glick, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Predictors of biomarker testing among patients (pts) with metastatic non-small cell lung cancer (mNSCLC).
    Robert, Nicholas J.
    Chen, Liwei
    Espirito, Janet L.
    Karhade, Mandar
    Evangelist, Makenzi Colleen
    Neubauer, Marcus A.
    Bullock, Susie A.
    Walberg, Jennifer M.
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy
    Altini, M.
    Massa, I.
    Balzi, W.
    Gentili, N.
    Foca, F.
    Danesi, V.
    Manunta, S.
    Ejzykowicz, F.
    Chandwani, S.
    Burgio, M.
    Cravero, P.
    Verlicchi, A.
    Bronte, G.
    Crino, L.
    Delmonte, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1065 - S1066
  • [9] Real World Experience of 1st Line Pembrolizumab in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Ansel, S.
    Mcloone, P.
    Steele, N.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S926 - S926
  • [10] A real-world analysis of non-small cell lung cancer patients treated with pembrolizumab or pembrolizumab in combination with pemetrexed and platinum
    Agg, Himani
    Winfree, Katherine B.
    Zhu, Yajun Emily
    Muehlenbein, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
12345